| Literature DB >> 35764677 |
Peter Piko1, Zsigmond Kosa2, Janos Sandor3, Ildiko Seres4, Gyorgy Paragh4, Roza Adany5,6.
Abstract
High-density lipoprotein cholesterol (HDL-C) is not a homogenous lipid fraction, but it can be further divided into subfractions. It is well-known that the Roma population has a high prevalence of reduced HDL-C levels and cardiovascular diseases (CVDs). However, it is unknown how this reduction affects different HDL subfractions, and whether changes in their quantity/representation are associated with an increased cardiovascular risk among them. In the present study, the HDL subfraction profile of the Hungarian general (HG) and the Roma populations were compared, and the subfractions showing a significant difference between the two populations were identified. The association of HDL subfractions with CVD risk estimated by the Framingham risk score (FRS) and the Systematic COronary Risk Evaluation (SCORE) algorithms were also defined. The present study is the first to find a significant association between HDL subfractions and cardiovascular risk estimated by FRS and SCORE. Ten HDL subfractions were investigated on small but carefully selected samples comprising 100 control subjects (with normal lipid profile) and 277 case subjects (with reduced HDL-C levels) from HG and Roma populations of a complex health survey. The level of HDL-1 to 3 subfractions and HDL-L showed a significant inverse association with cardiovascular risk estimated by both SCORE and FRS algorithms, whereas HDL-4 to 6 and HDL-I only for FRS. A higher representation (in %) of HDL-1 to 3 has a significant risk-reducing effect, while HDL-8 to 10 has a risk-increasing effect estimated by FRS. Our results confirmed that reduced levels of HDL-6 and -7 expressed in mmol/L were significantly associated with Roma ethnicity.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35764677 PMCID: PMC9240088 DOI: 10.1038/s41598-022-15192-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Flowchart showing the process of sample selection and biostatistical analyses.
Lipid and apolipoprotein profiles of study populations by HDL-C status (normal vs. reduced HDL-C levels).
| Normal HDL-C levels | Reduced HDL-C levels | |||||
|---|---|---|---|---|---|---|
| Hungarian general | Roma | Hungarian general | Roma | |||
| Mean (95% CI) | Mean (95% CI) | |||||
| HDL-C (mmol/L) | 1.62 (1.53–1.71) | 1.59 (1.49–1.70) | 0.290 | 1.02 (0.99–1.05) | 1.01 (0.98–1.03) | 0.678 |
| LDL-C (mmol/L) | 2.50 (2.33–2.67) | 2.63 (2.50–2.77) | 0.359 | 3.04 (2.86–3.23) | 3.17 (3.02–3.32) | 0.186 |
| TG (mmol/L) | 0.90 (0.80–0.99) | 0.88 (0.80–0.96) | 0.814 | 2.06 (1.84–2.28) | 1.88 (1.71–2.06) | 0.169 |
| TG/HDL-C ratio | 0.58 (0.51–0.66) | 0.59 (0.52–0.67) | 0.697 | 2.18 (1.89–2.46) | 2.00 (1.79–2.22) | 0.290 |
| Total cholesterol (mmol/L) | 4.39 (4.19–4.59) | 4.43 (4.26–4.60) | 0.871 | 4.79 (4.58–5.00) | 4.80 (4.63–4.97) | 0.978 |
| ApoAI (g/L) | 1.66 (1.58–1.74) | 1.62 (1.55–1.69) | 0.317 | 1.30 (1.27–1.33) | 1.27 (1.25–1.30) | 0.109 |
| ApoB (g/L) | 0.83 (0.77–0.88) | 0.87 (0.83–0.91) | 0.257 | 1.08 (1.03–1.14) | 1.12 (1.07–1.17) | 0.242 |
| ApoB/ApoAI ratio | 0.51 (0.47–0.55) | 0.55 (0.51–0.58) | 0.094 | 0.84 (0.80–0.88) | 0.89 (0.85–0.93) | 0.097 |
Threshold of significance after Bonferroni correction: p < 0.006.
95% CI, 95% confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein; TG, triglyceride; ApoAI, Apolipoprotein A1; ApoB, Apolipoprotein B.
Figure 2Composition of the HDL subfraction profile (in mmol/L and proportion in %) by HDL-C status (normal and reduced) in the Hungarian general and Roma populations. Large HDL: from HDL-1 to 3; intermediate HDL: from HDL-4 to 7; small HDL: from HDL-8 to 10. *Significant results after test correction (p < 0.002).
Effect of Roma ethnicity on HDL subfractions (A—in mmol/L and B—in %) compared to the Hungarian general one.
| 95% CI | |||
|---|---|---|---|
| HDL-1 | − 0.003 | − 0.008 to 0.003 | 0.342 |
| HDL-2 | − 0.012 | − 0.021 to − 0.003 | 0.009 |
| HDL-3 | − 0.005 | − 0.015 to 0.005 | 0.324 |
| HDL-4 | − 0.003 | − 0.012 to − 0.006 | 0.550 |
| HDL-5 | − 0.003 | − 0.009 to 0.003 | 0.296 |
| HDL-6 | − 0.016 | − 0.027 to − 0.006 | 0.003* |
| HDL-7 | − 0.008 | − 0.013 to − 0.003 | 0.002* |
| HDL-8 | − 0.006 | − 0.010 to − 0.002 | 0.007 |
| HDL-9 | < 0.001 | − 0.003 to 0.003 | 0.884 |
| HDL-10 | − 0.003 | − 0.013 to 0.006 | 0.502 |
| HDL-L | − 0.020 | − 0.041 to 0.001 | 0.066 |
| HDL-I | − 0.032 | − 0.059 to − 0.005 | 0.022 |
| HDL-S | − 0.008 | − 0.023 to 0.007 | 0.290 |
| HDL-1 | 0.027 | − 0.384 to 0.439 | 0.896 |
| HDL-2 | − 0.513 | − 0.957 to − 0.069 | 0.024 |
| HDL-3 | 0.131 | − 0.344 to 0.606 | 0.589 |
| HDL-4 | 0.190 | − 0.214 to 0.594 | 0.355 |
| HDL-5 | 0.200 | − 0.044 to 0.443 | 0.108 |
| HDL-6 | − 0.339 | − 0.788 to 0.110 | 0.139 |
| HDL-7 | − 0.204 | − 0.466 to 0.058 | 0.127 |
| HDL-8 | − 0.149 | − 0.386 to 0.088 | 0.218 |
| HDL-9 | 0.193 | − 0.010 to 0.397 | 0.063 |
| HDL-10 | 0.333 | − 0.394 to 1.060 | 0.368 |
| HDL-L | − 0.416 | − 1.419 to 0.587 | 0.415 |
| HDL-I | − 0.047 | − 0.682 to 0.588 | 0.884 |
| HDL-S | 0.418 | − 0.594 to 1.430 | 0.417 |
HDL-L, large HDL (from HDL-1 to 3); HDL-I, intermediate HDL (from HDL-4 to 7); HDL-S, small HDL (from HDL-8 to 10).
*Significant results after test correction (p < 0.004).
Effect of HDL subfractions (A—in mmol/L; B—in %) on the estimated cardiovascular risk by Systematic Coronary Risk Evaluation and Framingham Risk Scores.
| Systematic Coronary Risk Evaluation | Framingham Risk Scores | ||
|---|---|---|---|
| High-risk algorithm | CHD | CVD in general | |
| HDL-1 | − 11.26* | − 28.37* | − 53.98* |
| HDL-2 | − 6.27* | − 13.43* | − 24.99* |
| HDL-3 | − 5.95* | − 12.99* | − 23.85* |
| HDL-4 | − 4.84 | − 12.76* | − 23.23* |
| HDL-5 | − 8.50 | − 20.06* | − 39.80* |
| HDL-6 | − 5.10 | − 9.93* | − 19.9* |
| HDL-7 | − 8.85 | − 12.46 | − 25.98 |
| HDL-8 | − 8.61 | − 4.43 | − 14.83 |
| HDL-9 | − 6.17 | 11.85 | 10.57 |
| HDL-10 | 0.52 | 7.31 | 7.93 |
| HDL-L | − 2.65* | − 5.94* | − 10.94* |
| HDL-I | − 1.88 | − 4.32* | − 8.32* |
| HDL-S | − 0.81 | 2.48 | 1.84 |
| HDL-1 | − 0.13 | − 0.40* | − 0.71* |
| HDL-2 | − 0.08 | − 0.24* | − 0.41* |
| HDL-3 | − 0.10 | − 0.26* | − 0.42* |
| HDL-4 | − 0.10 | − 0.29* | − 0.45 |
| HDL-5 | 0.03 | − 0.18 | − 0.39 |
| HDL-6 | 0.04 | 0.18 | 0.33 |
| HDL-7 | 0.09 | 0.37 | 0.68 |
| HDL-8 | 0.13 | 0.54* | 0.92* |
| HDL-9 | 0.17 | 0.74* | 1.20* |
| HDL-10 | 0.07 | 0.18* | 0.29* |
| HDL-L | − 0.05 | − 0.12* | − 0.20* |
| HDL-I | 0.01 | 0.02 | 0.06 |
| HDL-S | 0.04 | 0.13* | 0.20* |
HDL-L, large HDL (from HDL-1 to 3); HDL-I, intermediate HDL (from HDL-4 to 7); HDL-S, small HDL (from HDL-8 to 10); CVD, cardiovascular diseases; CHD: coronary heart disease.
*Significant results after test correction (p < 0.004).
Figure 3.Composition of the HDL subfraction profile (proportion in % and in mmol/L) by low- and high-risk status according to Systematic Coronary Risk Evaluation and Framingham risk score—cardiovascular diseases in general. *Significant results after test correction (p < 0.0013).